Danaher Corp. closed 30.42% short of its 52-week high of $281.70, which the company achieved on August 1st.

Danaher Corporation DHR has been benefiting from strength in its bioprocessing business, driven by an increase in demand for consumables from large pharmaceutical customers in North America, Europe ...

Shares of Danaher Corp. slipped 5.54% to $186.81 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 1.61% to 5,844.61 and Dow Jones ...

DHR and AstraZeneca team up to develop AI-powered diagnostics, aiming to boost precision medicine by improving patient ...

Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An ...

Danaher Corporation (NYSE:DHR) and AstraZeneca PLC (NASDAQ:AZN) have announced a major partnership to accelerate the ...

Danaher Corporation, a key player in Life Sciences, Biotechnology, and Diagnostics, has shown mixed financial performance with recent declines in revenue and net earnings. Despite recent struggles ...

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments ...

Danaher Corporation incorporates science and technology and has a market cap of $150B. The company has mixed financials, with its gross profit margin being its strongest and most consistent.

SCIEX Sets a New Standard in Accurate Mass Quantitation With the ZenoTOF 8600 System and New Software Collaborations ...

Last week, readers were most interested in a story about what's up Roche's sleeve as it talked about its plans during its investor day.